Drugs for Erectile Dysfunction Global Market Report 2024

The drugs for erectile dysfunction market size has grown marginally in recent years. It will grow from $4.12 billion in 2023 to $4.17 billion in 2024 at a compound annual growth rate (CAGR) of 1.2%. The growth observed in the historic period can be attributed to several factors, including the introduction of PDE5 inhibitors (phosphodiesterase type 5 inhibitors), pharmaceutical marketing and advertising strategies, evolving societal attitudes towards erectile dysfunction (ED), an increase in cases of ED induced by lifestyle factors, and the availability of generic medications in the market.

The drugs for erectile dysfunction market size is expected to see marginal growth in the next few years. It will grow to $4.46 billion in 2028 at a compound annual growth rate (CAGR) of 1.7%. Forecasted growth is driven by mental health integration, changing consumer preferences, emerging market expansion, regenerative medicine exploration, and biopharmaceutical innovations. Major trends include novel therapy development, heightened awareness, lifestyle changes, telemedicine, and innovative delivery systems.

The significant rise in the number of chronic diseases is a key driver for the erectile dysfunction drug market. Erectile dysfunction is primarily linked to chronic conditions resulting from a sedentary lifestyle, such as cardiovascular diseases, diabetes, obesity, and high blood pressure. As reported by the World Health Organization (WHO) in September 2023, chronic diseases are responsible for 41 million deaths annually, accounting for 74% of all global deaths. The prevalence of chronic diseases heightens the likelihood of erectile dysfunction among men, consequently propelling the market for erectile dysfunction drugs.

The increasing prevalence of hypertension is anticipated to fuel the growth of the drugs for erectile dysfunction market in the foreseeable future. Hypertension, characterized by sustained high blood pressure against the artery walls, is a prevalent medical condition. Erectile dysfunction drugs, such as sildenafil, contribute to managing hypertension by improving blood vessel function, lowering blood pressure, and promoting overall cardiovascular health through enhanced blood flow. For instance, the World Health Organization (WHO) reported in March 2023 that an estimated 1.28 billion adults aged 30–79 years worldwide have hypertension, with two-thirds residing in low- and middle-income countries. Hence, the escalating prevalence of hypertension is a driving factor in the growth of the drugs for erectile dysfunction market.

Adverse effects linked to erectile dysfunction drugs have negatively impacted the market's growth during the forecast period. These side effects may contribute to decreased patient adherence and raise concerns among healthcare professionals, resulting in reduced adoption and trust in the medications, thereby impeding market expansion. A study conducted by RxList Inc., a US-based healthcare company, in July 2022, involving 511 men who experienced recurring side effects following Viagra consumption, highlighted common issues such as headaches, flushing, indigestion, and nasal congestion. Notably, 21% of patients experienced headaches, 19% experienced flushing, 9% experienced dyspepsia, and other side effects were reported, indicating potential challenges associated with drug side effects.

Several companies in the erectile dysfunction drugs market are implementing new drug delivery techniques, such as pellets and creams. These innovations offer increased efficacy, performance, and safety in treating erectile dysfunction. For example, in September 2022, Lupin, an India-based pharmaceutical company, launched Sildenafil for oral suspension, 10 mg/mL, approved by the United States Food and Drug Administration (FDA). This drug delivery method provides unique dosages for treating erectile dysfunction, enhancing treatment options and potentially addressing concerns related to side effects.

Major players in the drugs for erectile dysfunction market are strategically focusing on introducing combination capsules, such as therapy capsules, to optimize revenue. Tamsulosin and Tadalafil, a combination of medications targeting benign prostatic hyperplasia (BPH) and erectile dysfunction, is gaining prominence. In September 2023, Akums Drugs & Pharmaceuticals Ltd., an India-based pharmaceutical company, launched a therapy capsule addressing both conditions in the Indian market. This capsule, containing a combination of Tamsulosin and Tadalafil, demonstrates significant improvements in BPH and the Erectile Dysfunction Index. The introduction of such therapy capsules provides a novel treatment option for patients grappling with both conditions, catering to a broader spectrum of needs in the market.

Major companies operating in the drugs for erectile dysfunction market report are Pfizer Inc., Johnson & Johnson Services Inc., Bayer AG, Sanofi S.A., GlaxoSmithKline PLC, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Boston Scientific Corporation, Sun Pharmaceutical Industries Limited, Coloplast A/S, Cipla Limited, Endo International PLC, Lupin Limited, Glenmark Pharmaceuticals Limited, S.K. Chemicals Co. Ltd., Dong A Pharmaceutical Co. Ltd., Zephyr Surgical Implants, Seelos Therapeutics Inc., Premedon, Meda Pharmaceuticals Inc., Futura Medical PLC, Augusta Medical Systems LLC, Vivus Inc., Apricus Biosciences Inc., Bonro Medical Inc., Cristalia Produtos Quimicos Farmaceuticos Ltda., Post-T-Vac Medical Inc., Adamed Pharma SA, Produtos Quimicos Farmaceuticos Ltda., Metuchen Pharmaceuticals LLC, Revive Pharmaceuticals Pvt. Ltd., Viatris Specialty LLC.

North America was the largest region in the drugs for erectile dysfunction market in 2023. Middle East is expected to be the fastest-growing region in the global drugs for erectile dysfunction market during the forecast period. The regions covered in the drugs for erectile dysfunction market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the drugs for erectile dysfunction market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Various types of ED drugs include sildenafil citrate, mirodenafil, and vardenafil. Sildenafil, available under trade names such as Viagra, is used to treat erectile dysfunction and pulmonary arterial hypertension. Its effectiveness in treating female genital dysfunction remains uncertain. These drugs can be administered orally, topically, or via injections, and are commonly distributed through hospital pharmacies, retail pharmacies, and online platforms.

The drugs for erectile dysfunction market research report is one of a series of new reports that provides drugs for erectile dysfunction market statistics, including drugs for erectile dysfunction industry global market size, regional shares, competitors with drugs for erectile dysfunction market share, detailed drugs for erectile dysfunction market segments, market trends and opportunities, and any further data you may need to thrive in the drugs for erectile dysfunction industry. This drugs for erectile dysfunction market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The erectile dysfunction (ED) drugs market consists of sales Sildenafil (Viagra), vardenafil (Levitra, Staxyn), tadalafil (Cialis) and avanafil (Stendra). Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.